#dive

Related news

Allergan touts new data from failed NASH study

Published: 22/09/2017

Cenicriviroc didn't meet the CENTAUR study's primary endpoint, but did show benefit in liver fibrosis. Read more

Source: www.biopharmadive.com
Prescribed Reading: Consolidation, clinical holds and landmark results

Published: 22/09/2017

The FDA continues its clinical hold spree for PD-1/L1s, consolidation is rampant in the CDMO space and RNAi may become a reality very soon. Read more

Source: www.biopharmadive.com
Cellectar, Onconova partner on cancer drug conjugates

Published: 22/09/2017

An early-stage collaboration could boost the two small-cap biotechs' pipelines. Read more

Source: www.biopharmadive.com

Big pharma builds blockchain prototype to stop counterfeits

Published: 21/09/2017

The MediLedger Project brings together pharma supply chain stakeholders like Pfizer and McKesson to build a system that could register and verify drugs. Read more

Source: www.biopharmadive.com
Korean drugmaker used employees to test potentially harmful ointment, FDA says

Published: 21/09/2017

Firson Co. Ltd. is one of two Asian pharma manufacturers recently flagged by the agency for manufacturing violations. Read more

Source: www.biopharmadive.com
Brammer Bio doubles manufacturing capacity at Florida site

Published: 21/09/2017

Completion of the expansion should help the gene therapy CDMO better support early-stage clinical trials. Read more

Source: www.biopharmadive.com

PhRMA report highlights failures in AD development

Published: 21/09/2017

While biotech holds its breath for results from Axovant, PhRMA's report showcases just how hard it is to bring a new treatment for Alzheimer's disease to market. Read more

Source: www.biopharmadive.com
Alzheimer's drug development just as challenging as ever

Published: 21/09/2017

While biotech holds its breath for results from Axovant, a report from PhRMA showcases how hard it is to bring a new treatment to market. Read more

Source: www.biopharmadive.com
Provention builds pipeline with Janssen licensing deal

Published: 21/09/2017

Launched earlier this year, Provention now boasts a pipeline of three in-licensed drug candidates. Read more

Source: www.biopharmadive.com

Fortune's Most Powerful Women list stresses gender gap in pharma

Published: 21/09/2017

Only three pharma executives made the Fortune list, highlighting the gender inequalities that pharma continues to struggle with. Read more

Source: www.biopharmadive.com
Swedish CDMO picks up facility, supply contract in deal with Roche

Published: 21/09/2017

Roche has offloaded several small molecule-focused sites in a shift toward biologics production. Read more

Source: www.biopharmadive.com
Judge denies PhRMA, BIO jab at Nevada law

Published: 20/09/2017

The trade groups didn't convince Judge James Mahan that a temporary restraining order was warranted for the state's diabetes drug pricing transparency bill. Read more

Source: www.biopharmadive.com

House members urge Trump to lower cost of opioid overdose antidote

Published: 20/09/2017

Prices of new naloxone formulations, such as Kaleo's Evzio, have risen in recent years, drawing scrutiny from lawmakers. Read more

Source: www.biopharmadive.com
Teva teams up with Nuvelution in Tourette

Published: 20/09/2017

The companies are planning a late-stage program that will evaluate Austedo, which has already locked down two indications this year, as a treatment for children with the syndrome. Read more

Source: www.biopharmadive.com
Alnylam soars on trial win for RNAi drug

Published: 20/09/2017

Patisiran's success marks a major milestone for the Cambridge biotech, which has spent 15 years developing the science behind its RNA interference approach. Read more

Source: www.biopharmadive.com

Bayer ends sales of Essure implant outside of US

Published: 19/09/2017

The drugmaker said the decision was unrelated to the safety or efficacy of the contraceptive, which has been the subject of numerous consumer complaints. Read more

Source: www.biopharmadive.com
Split adcomm vote leaves Pfizer's Sutent in limbo

Published: 19/09/2017

An FDA advisory panel voted six in favor, six against a new indication for the drugmaker's cancer med. Read more

Source: www.biopharmadive.com
Juniper rushes to save costs with job cuts

Published: 19/09/2017

Women's health company Juniper is focusing to its core program, cutting jobs and seeking partners in a bid to increase cash flow. Read more

Source: www.biopharmadive.com

Catalent adds biologics manufacturing with $950M Cook Pharmica deal

Published: 19/09/2017

The contract developer is expanding its capabilities to encompass development through commercialization. Read more

Source: www.biopharmadive.com
Supernus tweaks ADHD studies to boost chances of success

Published: 19/09/2017

A planned interim analysis prompted the Maryland specialty pharma to drop a low dose of its drug for impulsive aggression in two Phase 3 trials. Read more

Source: www.biopharmadive.com
Teva offloads the rest of its women's health business for $1.4B

Published: 19/09/2017

The deals put Teva past its goal of selling $2 billion worth of assets by year's end. Read more

Source: www.biopharmadive.com

Related Hashtags

Most read

FACEBOOK

Facebook

Place your ad here
Loading...